Technical Analysis for VAXX - Vaxxinity, Inc.

Grade Last Price % Change Price Change
D 9.11 24.45% 1.79
VAXX closed up 24.45 percent on Tuesday, December 7, 2021, on 3.7 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical VAXX trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
New 52 Week Closing Low Bearish 24.45%
Hot IPO Pullback Bullish Swing Setup 24.45%
New 52 Week Low Weakness 24.45%
Down 3 Days in a Row Weakness 24.45%
Down 4 Days in a Row Weakness 24.45%
Down 5 Days in a Row Weakness 24.45%
New 52 Week Closing Low Bearish 3.29%
Hot IPO Pullback Bullish Swing Setup 3.29%
Older End-of-Day Signals for VAXX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Pocket Pivot about 14 hours ago
Hot IPO Pullback Entry about 15 hours ago
Rose Above Previous Day's High about 15 hours ago
2x Volume Pace about 15 hours ago
1.5x Volume Pace about 15 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vaxxinity, Inc. Description

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Alzheimer's Disease Parkinson's Disease Neurological Disorders Dementia Amyloidosis Neurodegenerative Disorders Lewy Body Dementia Lewy Body Multiple System Atrophy Neuropathology Pcsk9

Is VAXX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 22.77
52 Week Low 7.11
Average Volume 596,562
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 12.40
Average True Range 2.60
ADX 0.0
+DI 12.76
-DI 25.69
Chandelier Exit (Long, 3 ATRs) 14.98
Chandelier Exit (Short, 3 ATRs) 14.90
Upper Bollinger Bands 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line -2.12
MACD Signal Line -1.13
MACD Histogram -0.9906
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.87
Resistance 3 (R3) 11.74 10.70 11.41
Resistance 2 (R2) 10.70 9.99 10.76 11.26
Resistance 1 (R1) 9.90 9.56 10.30 10.03 11.10
Pivot Point 8.86 8.86 9.06 8.92 8.86
Support 1 (S1) 8.06 8.15 8.46 8.19 7.12
Support 2 (S2) 7.02 7.72 7.08 6.96
Support 3 (S3) 6.22 7.02 6.81
Support 4 (S4) 6.35